Fecal Pills

A study shows that fecal transplants in an oral capsule form are an effective treatment for Clostridium difficile infection.

Written byAbby Olena, PhD
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

PUBLIC HEALTH IMAGE LIBRARY, CDCClostridium difficile (C. diff) infection can cause severe diarrhea and cramping, often leading to hospitalization. Transplantation of donor feces containing normal gut bacteria via enema, colonscopy, or nose tube has been shown to be an effective treatment for this often recurring infection. But a report presented this month (October 3) at IDWeek 2013, an international meeting of infectious disease specialists in San Francisco, has shown that less off-putting oral fecal capsules also work.

A University of Calgary group, let by physician Thomas Louie, used centrifugation to collect sediment containing beneficial microbes from feces of healthy donors (usually patient relatives) and then packaged the sediment in gelatin capsules. Patients who had experienced at least three severe C. diff infections took one dose of two to three dozen fecal pills over about 15 minutes on an empty stomach. None of the 27 patients who received the treatment in 2010 has since relapsed.

“The approach that Dr. Louie has is completely novel—no one else has done this,” Curtis Donskey, an associate professor of medicine at Case Western Reserve University in Cleveland and a physician the Cleveland Veterans Affairs Medical Center, told the Associated Press. “I am optimistic that this type of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • abby olena

    As a freelancer for The Scientist, Abby reports on new developments in life science for the website. She has a PhD from Vanderbilt University and got her start in science journalism as the Chicago Tribune’s AAAS Mass Media Fellow in 2013. Following a stint as an intern for The Scientist, Abby was a postdoc in science communication at Duke University, where she developed and taught courses to help scientists share their research. In addition to her work as a science journalist, she leads science writing and communication workshops and co-produces a conversational podcast. She is based in Alabama.  

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies